Core Insights - Becton, Dickinson and Co. (BDX) is a multinational medical technology company focused on manufacturing and selling medical devices, instruments, and reagents globally [1] Financial Performance - The company is set to report its Q4 2025 earnings on November 6, with analysts expecting an EPS of $3.92, an increase from $3.81 in the prior year [2] - Quarterly revenue is anticipated to reach $5.92 billion, up from $5.44 billion a year earlier [2] - In Q3 2025, Becton Dickinson reported an adjusted EPS of $3.68, exceeding the consensus estimate of $3.41, and revenues of $5.51 billion, slightly above the consensus of $5.49 billion [3] Growth and Strategic Initiatives - The CEO highlighted an increase in organic growth trajectory in Q3, along with strong margin and EPS growth, which led to a raised EPS guidance for the full year [4] - The full-year 2025 adjusted EPS guidance has been raised to a range of $14.30 to $14.45, reflecting a $0.18 increase and a 9.4% growth at the midpoint [4] - An agreement was announced to combine BD's Biosciences and Diagnostic Solutions business with Waters Corporation, aimed at creating a leader in life sciences and diagnostics focused on high-volume testing [4]

Core Insights - Becton, Dickinson and Company (BDX) has announced a multi-year collaboration with Opentrons Labworks to integrate robotic liquid-handling capabilities into its single-cell multiomics instruments, aiming to automate critical experimental steps for disease research and drug development [1][5][8] - This partnership is expected to enhance BD's Biosciences (BDB) business unit and strengthen its position in the niche market of lab automation [2][8] - Despite the potential benefits of the collaboration, BDX's stock experienced a decline of nearly 1.8% following the announcement [3] Company Performance - BD currently has a market capitalization of $54.19 billion and an earnings yield of 7.8%, which is higher than the industry average of 6.4% [4] - In the last reported quarter, BDX achieved an earnings surprise of 7.6% [4] - Over the past year, BD's shares have decreased by 19.8%, contrasting with a 2.7% rise in the industry and a 17.8% gain in the S&P 500 [10] Partnership Details - The collaboration aims to integrate the BD Rhapsody System with the Opentrons Flex platform, allowing for hands-free workflows in single-cell multiomics experiments [5][6] - An automation-compatible module for the BD Rhapsody System is expected to automate next-generation sequencing library preparation and cell capture [5][6] Industry Prospects - The global sequencing market is projected to grow from $15.54 billion in 2023 to $62.48 billion by 2030, at a CAGR of 22.2%, driven by increasing demand for gene therapy and consumer genomics [7] - The partnership with Opentrons is anticipated to significantly boost BD's business in light of the favorable market conditions [7]

9k+ Digital Media Outlets 270k+ Journalists Opted In Media: Investors: Fallon McLoughlin Adam Reiffe Director, Public Relations Vice President, Investor Relations 201.258.0361 201.847.6927        [email protected] [email protected]     SOURCE BD (Becton, Dickinson and Company) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD ...

Core Insights - BD has enrolled the first patient in the XTRACT™ Registry, a study aimed at evaluating the real-world performance of the Rotarex™ Catheter System for treating peripheral artery disease (PAD) [1][2][4] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery [6] - The company employs over 70,000 individuals and operates in nearly every country, addressing significant global health challenges [6] XTRACT™ Registry Details - The XTRACT™ Registry is a prospective, multi-center, single-arm study designed to collect data on the Rotarex™ Catheter System's effectiveness in treating PAD [1][2] - The registry aims to enroll up to 600 patients across 100 clinical sites in the U.S., with follow-up evaluations at 30 days, six months, and 12 months post-procedure [3][4] Rotarex™ Catheter System Features - The Rotarex™ Catheter System utilizes three mechanisms of action to effectively remove plaque and thrombus, functioning as both an atherectomy and thrombectomy device [4] - The device is designed to enhance patient outcomes by modifying and detaching mixed morphology lesions while actively aspirating material away [4] Market Context - PAD affects over 21 million Americans and more than 200 million people globally, with untreated cases leading to serious cardiovascular complications [5]

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recognized worldwide for accessible lab automation with more than 10,000 robotic systems deployed, today announced a multi-year collaboration. Together, BD and Opentrons will integrate robotic liquid-handling capabilities into BD single-cell multiomics instruments, automating critical experimental steps to accelerate and scale disease research and drug development. BD ...

Accessibility StatementSkip Navigation SUMTER, S.C., Oct. 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today will commemorate 55 years of manufacturing excellence at its Sumter, South Carolina facility, which throughout its history has been a core site within the Company's extensive U.S. manufacturing footprint. Continue Reading BD Celebrates 55 Years of Manufacturing Excellence and Impact in Sumter, S.C. About BD Vacutainer productsBD ...

Core Insights - Becton, Dickinson and Company (BD) has formed a pharmacy automation partnership with Henry Ford Health to improve medication storage and prescription delivery, focusing on a robotic solution for 24/7 prescription pickup [1][9] Company Developments - The collaboration will utilize the BD Rowa Vmax pharmacy automation robot, initially enhancing prescription retrieval at Henry Ford Health's community pharmacies in Southeast and Central Michigan [2][4] - This partnership is a strategic move for BD to strengthen its Pharmacy Automation business within the Medication Management Solutions (MMS) unit of the BD Medical segment [3][9] - BD's management highlights the Rowa Vmax's reputation for high-speed, modular robotic storage, which is expected to improve patient access to prescriptions [4] Industry Prospects - The global pharmaceutical automation market is projected to grow from $8.38 billion in 2024 to $19.03 billion by 2032, with a compound annual growth rate (CAGR) of 10.8%, driven by increased robot usage and technological advancements [6] - The partnership with Henry Ford Health is anticipated to significantly enhance BD's position in this growing market [6] Performance Comparison - BD's MMS business unit reported solid growth in Pharmacy Automation during its third-quarter fiscal 2025 results, indicating robust performance in the sector [7] - Competitors such as Omnicell, McKesson, and Baxter International have also reported strong financial results and advancements in their pharmacy automation offerings, highlighting a competitive landscape [8][10][11]

Core Insights - BD (Becton, Dickinson and Company) has announced a pharmacy automation partnership with Henry Ford Health to create a future-oriented pharmacy system, focusing on a robotic solution for 24/7 prescription pickup [1][2]. Group 1: Partnership Details - The collaboration will utilize the BD Rowa™ Vmax, a high-capacity pharmacy automation robot, to improve prescription retrieval processes at Henry Ford Health's community pharmacies in Southeast and Central Michigan [2][3]. - This partnership aims to enhance patient-centered care and innovation within the health system pharmacy [3][4]. Group 2: Benefits of Automation - The BD Rowa™ Vmax is designed for high-speed, modular storage and dispensing of medications, which will improve patient access to prescriptions and streamline pharmacy operations [3][6]. - Key benefits include 24/7 prescription access, real-time tracking, and improved efficiency for pharmacy staff, allowing them to focus on higher-value patient care tasks [6][4]. Group 3: Company Overview - BD is one of the largest global medical technology companies, dedicated to advancing health through innovative technologies and solutions that enhance clinical therapy and care delivery [5][7]. - The company employs over 70,000 individuals and collaborates globally to address significant health challenges, aiming to improve outcomes and lower costs in healthcare [5][7].

Group 1 - Becton, Dickinson and Company (BDX) is recognized as a medical technology company currently undergoing a turnaround due to past challenges, including strategic missteps and a significant product recall [2][3] - The company has acquired the critical care product group from Edwards Lifesciences to enhance its core business and plans to spin off its biosciences and diagnostic solutions division, which is set to be purchased by Waters in a deal expected to close by 2026 [3] - BDX has a strong dividend history, with a 53-year track record of consistent payments, offering a quarterly dividend of $1.04 per share and a dividend yield of 2.22% as of September 19 [5] Group 2 - The planned spinoff of the biosciences and diagnostic solutions division is projected to be accretive to earnings in its first year, suggesting that the dividend should remain stable throughout the transition [4]

Core Insights - BD (Becton, Dickinson and Company) has successfully placed its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital, marking a significant milestone in the adoption of its single-cell multiomics analysis technology [1][2]. Company Overview - BD is recognized as one of the largest global medical technology companies, focusing on improving medical discovery, diagnostics, and care delivery [5]. - The company employs over 70,000 individuals and operates in virtually every country, partnering with organizations to tackle global health challenges [5]. Product Highlights - The BD Rhapsody™ System, introduced in 2017, has been cited in over 700 peer-reviewed publications, demonstrating its impact in the scientific community [2]. - The latest version of the BD Rhapsody™, launched in 2023, features advanced sample processing and cell capture technologies, enhancing the efficiency of next-generation sequencing applications [2]. - Upcoming innovations include the BD OMICS-One™ WTA Next Assay for unlocking genetic information at a lower cost and BD® OMICS-Guard Cryo for sample preservation [6]. Market Demand - The rapid adoption of the BD Rhapsody™ System reflects a critical need for high-performing multiomic assays that maintain data quality while being cost-effective [3]. - The system is positioned to work seamlessly with leading cell sorters and analyzers, indicating a comprehensive end-to-end solution for single-cell analysis [3]. Research and Development - Research conducted by Dr. Andrew Conway Morris at Addenbrooke's Hospital aims to understand immune cell signaling pathways, with the BD Rhapsody™ System facilitating advanced analysis at the single-cell level [2]. - The company continues to innovate its workflows and product offerings to meet the evolving scientific needs [3]. Upcoming Events - The BD Rhapsody™ System will be showcased at the 2025 Annual Meeting of the American Society of Human Genetics and at Advancing Precision Medicine [4].